Free Fatty Acids Differentially Downregulate Chemokines in Liver Sinusoidal Endothelial Cells: Insights into Non-Alcoholic Fatty Liver Disease
Open accessThe DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease is a prevalent problem throughout the western world. Liver sinusoidal endothelial cells (LSEC) have been shown to play important roles in liver injury and repair, but their role in the underlying pathogenetic mechanisms of non-alcoholic fatty liver disease remains undefined. Here, we evaluated the effects of steatosis on LSEC gene expression in a murine model of non-alcoholic fatty liver disease and an immortalized LSEC line. Using microarray we identified distinct gene expression profiles following exposure to free fatty acids. Gene pathway analysis showed a number of differentially expressed genes including those involved in lipid metabolism and signaling and inflammation. Interestingly, in contrast to hepatocytes, fatty acids led to decreased expression of pro-inflammatory chemokines including CCL2 (MCP-1), CXCL10 and CXCL16 in both primary and LSEC cell lines. Chemokine downregulation translated into a significant inhibition of monocyte migration and LSECs isolated from steatotic livers demonstrated a similar shift towards an anti-inflammatory phenotype. Overall, these pathways may represent a compensatory mechanism to reverse the liver damage associated with non-alcoholic fatty liver disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Therefore, LSECs play a key role in immunomodulation in the liver and many of these leukocyte migration axes are upregulated in NASH.140,141”
From Understanding the cellular interactome of non-alcoholic fatty liver disease (2022) · cites this paper as [140]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Mutation of the mouse klotho gene leads to a syndrome resembling ageing
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,803
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 3×
“In addition, elevated levels of the saturated palmitic acid (PA) and the mono-unsaturated oleic acid (OA) are found in NAFLD patients and make up a majority of the FFA in TAG [3,6].”
Kanda, H. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26498 · Cited by 2,682 · cited 1×
“As the pathogenesis of NAFLD has been clearly linked with the recruitment of pro-inflammatory monocytes to the liver, we focused on CCL2 whose genetic absence has been shown to abrogate NAFLD [23].”
A lipidomic analysis of nonalcoholic fatty liver disease
Puri, P., Baillie, R. A., Wiest, M. M., Mirshahi, F., Choudhury, J., Cheung, O., Sargeant, C., Contos, M. J., & Sanyal, A. J. (2007) · Hepatology · doi:10.1002/hep.21763 · Cited by 1,338
Postic, C., & Girard, J. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34275 · Cited by 1,204 · cited 1×
“NAFLD is characterized by increased hepatic accumulation of lipids, likely resulting from multiple factors including lipolysis from adipocytes or increased intake of dietary fat followed by enhanced FFA production, as well as de novo lipogenesis and impaired lipid disposal [3,28].”
Tsou, C.-L., Peters, W., Si, Y., Slaymaker, S., Aslanian, A. M., Weisberg, S. P., Mack, M., & Charo, I. F. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29919 · Cited by 1,152 · cited 1×
“CCL7 has been shown to be important for the recruitment of Ly6C high pro-inflammatory monocytes to inflamed tissues [21], whereas CXCL16 is a chemoattractant for NKT cells [22].”
Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD)
MUSSO, G., GAMBINO, R., & CASSADER, M. (2009) · Progress in Lipid Research · doi:10.1016/j.plipres.2008.08.001 · Cited by 681
A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo
Matloubian, M., David, A., Engel, S., Ryan, J. E., & Cyster, J. G. (2000) · Nature Immunology · doi:10.1038/79738 · Cited by 661 · cited 1×
“CCL7 has been shown to be important for the recruitment of Ly6C high pro-inflammatory monocytes to inflamed tissues [21], whereas CXCL16 is a chemoattractant for NKT cells [22].”
Cited by
Liver sinusoidal endothelial cells — gatekeepers of hepatic immunity
Shetty, S., Lalor, P. F., & Adams, D. H. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0020-y · Cited by 523
“This importance makes them and the molecules they express attractive therapeutic targets in inflammatory liver disease 147, 148 .”
BackgroundUnderstanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?
Rada, P., González-Rodríguez, Á., García-Monzón, C., & Valverde, Á. M. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-03003-w · Cited by 518
Role of liver sinusoidal endothelial cells in non-alcoholic fatty liver disease
Hammoutene, A., & Rautou, P.-E. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.012 · Cited by 364
Macrophage functional diversity in NAFLD — more than inflammation
Barreby, E., Chen, P., & Aouadi, M. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00675-6 · Cited by 247
He, Y., Hwang, S., Cai, Y., Kim, S., Xu, M., Yang, D., Guillot, A., Feng, D., Seo, W., Hou, X., et al. (2019) · Hepatology · doi:10.1002/hep.30645 · Cited by 149
Endothelial Cell Dysfunction and Nonalcoholic Fatty Liver Disease (NAFLD): A Concise Review
Nasiri-Ansari, N., Androutsakos, T., Flessa, C.-M., Kyrou, I., Siasos, G., Randeva, H. S., Kassi, E., & Papavassiliou, A. G. (2022) · Cells · doi:10.3390/cells11162511 · Cited by 131
Understanding the cellular interactome of non-alcoholic fatty liver disease
Wallace, S. J., Tacke, F., Schwabe, R. F., & Henderson, N. C. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100524 · Cited by 116
“Therefore, LSECs play a key role in immunomodulation in the liver and many of these leukocyte migration axes are upregulated in NASH.(140,141) One key observation in the progression of cirrhosis is the loss”
BackgroundCrosstalk Between Liver Macrophages and Surrounding Cells in Nonalcoholic Steatohepatitis
Li, H., Zhou, Y., Wang, H., Zhang, M., Qiu, P., Zhang, M., Zhang, R., Zhao, Q., & Liu, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01169 · Cited by 114
“Kupffer Cells–Liver Sinusoidal Endothelial Cells At the early stage of NAFLD, LSECs exhibited an antiinflammatory property by inhibiting KC activation and monocyte migration (81, 82).”
BackgroundAngiocrine signaling in sinusoidal homeostasis and liver diseases
Gao, J., Lan, T., Kostallari, E., Guo, Y., Lai, E., Guillot, A., Ding, B., Tacke, F., Tang, C., & Shah, V. H. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.05.014 · Cited by 90
SECs (Sinusoidal Endothelial Cells), Liver Microenvironment, and Fibrosis
Natarajan, V., Harris, E. N., & Kidambi, S. (2017) · BioMed Research International · doi:10.1155/2017/4097205 · Cited by 84
“Fibrosis is also influenced by a reversal of LSEC function from tolerogenic to proinflammatory and immunogenic; this phenomenon contributes to both heightened inflammatorymilieu and altered intrahepatic immunity [32, 33].”
BackgroundChemokines in Non-alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis
Pan, X., Kaminga, A. C., Liu, A., Wen, S. W., Chen, J., & Luo, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01802 · Cited by 87
“They have been shown to be involved in various biological processes of NAFLD pathophysiology, including chemotaxis, which not only regulates the migration and activities of immune cell to the site of inflammation but also mediates the secretion and production of inflammatory mediators and activates the lymphoid tissue…”
BackgroundOxidative Stress and Redox Signaling in the Pathophysiology of Liver Diseases
Mooli, R. G. R., Mukhi, D., & Ramakrishnan, S. K. (2022) · Comprehensive physiology · doi:10.1002/cphy.c200021 · Cited by 152
Kus, E., Kaczara, P., Czyzynska-Cichon, I., Szafranska, K., Zapotoczny, B., Kij, A., Sowinska, A., Kotlinowski, J., Mateuszuk, L., Czarnowska, E., et al. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00006 · Cited by 61
Ullah, A., Din, A. U., Ding, W., Shi, Z., Pervaz, S., & Shen, B. (2023) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09800-w · Cited by 66
“Prior research has found that CXCL16 is substantially expressed in the livers of patients who suffer from metabolic and inflammatory liver disorders [206, 207] and that CXCL16 inhibition reduced steatohepatitis and liver macrophage infiltration in chronic hepatic damage [208].”
BackgroundLiver sinusoidal endothelial cells (LSECs) modifications in patients with chronic hepatitis C
Baiocchini, A., Del Nonno, F., Taibi, C., Visco-Comandini, U., D’Offizi, G., Piacentini, M., & Falasca, L. (2019) · Scientific Reports · doi:10.1038/s41598-019-45114-1 · Cited by 58
Endothelial dysfunction in pathological processes of chronic liver disease during aging
Wan, Y., Li, X., Slevin, E., Harrison, K., Li, T., Zhang, Y., Klaunig, J. E., Wu, C., Shetty, A. K., Dong, X. C., et al. (2022) · The FASEB Journal · doi:10.1096/fj.202101426r · Cited by 53
The role of liver sinusoidal endothelial cells in cancer liver metastasis.
Yang, M. J., & Zhang, C. (2021) · American Journal of Cancer Research · Cited by 75
Endo‐Umeda, K., Nakashima, H., Komine‐Aizawa, S., Umeda, N., Seki, S., & Makishima, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-27615-7 · Cited by 57
Gut Microbiome in Non-Alcoholic Fatty Liver Disease: From Mechanisms to Therapeutic Role
Gupta, H., Min, B.-H., Ganesan, R., Gebru, Y. A., Sharma, S. P., Park, E., Won, S., Jeong, J., Lee, S.-B., Cha, M., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10030550 · Cited by 56
“These chemokines also mediate the production and secretion of inflammatory mediators and promote lymphoid tissue maturation [87].”
BackgroundEmerging Roles of Liver Sinusoidal Endothelial Cells in Nonalcoholic Steatohepatitis
Furuta, K., Guo, Q., Hirsova, P., & Ibrahim, S. H. (2020) · Biology · doi:10.3390/biology9110395 · Cited by 48
“LSEC play an anti-inflammatory role early on during NAFLD development by decreasing pro-inflammatory chemokine secretion [13].”
BackgroundZhou, C., Shen, Z., Shen, B., Dai, W., Sun, Z., Guo, Y., Xu, X., Wang, J., Lu, J., Zhang, Q., et al. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166810 · Cited by 46
Wang, X.-K., & Peng, Z.-G. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.655557 · Cited by 40
“…for the survival of LSECs in the case of lipid induction, and it also may be involved with signal transducer and activator of transcription 3 (STAT3) for its expression in LSECs alleviated mice liver inflammation induced by alcohol (Miller et al., 2010; Hang et al., 2012; McMahan et al., 2016).”
BackgroundSingle-cell RNA sequencing identifies a population of human liver-type ILC1s
Krämer, B., Nalin, A. P., Ma, F., Eickhoff, S., Lutz, P. L., Leonardelli, S., Goeser, F., Finnemann, C., Hack, G., Raabe, J., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2022.111937 · Cited by 47
“…and 10% FCS. Primary human liver sinusoidal epithelial cells(LSECs), primary hepatic stellate cells(HSC), and primary hepatocytes were purchased 53,54 (Sciencell, USA) and expanded with endothelial cell medium, stellate cell medium or hepatocyte medium(Sciencell, USA), respectively, to passage…”
Burchill, M. A., Roby, J. A., Crochet, N., Wind‐Rotolo, M., Stone, A. E. L., Edwards, M. G., Dran, R. J., Kriss, M. S., Gale, M., & Rosen, H. R. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186213 · Cited by 39
Self-citationThe microenvironment in the development of MASLD-MASH-HCC and associated therapeutic in MASH-HCC
Wu, Q., Yang, Y., Lin, S., Geller, D. A., & Yan, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1569915 · Cited by 32
Vachliotis, I. D., & Pοlyzos, S. A. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00657-5 · Cited by 33
“Interestingly, LSECs appear to reduce MCP-1 expression in response to hepatic steatosis, presumably as a compensatory mechanism [133].”
Endo-Umeda, K., Nakashima, H., Umeda, N., Seki, S., & Makishima, M. (2018) · Endocrinology · doi:10.1210/en.2017-03141 · Cited by 28
Dai, Q., Ain, Q., Seth, N., Rooney, M., & Zipprich, A. (2025) · Digestive and Liver Disease · doi:10.1016/j.dld.2025.01.189 · Cited by 31
Gehrke, N., Hofmann, L. J., Straub, B. K., Rühle, F., Waisman, A., Galle, P. R., & Schattenberg, J. M. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.1048 · Cited by 23
Jiang, L., Yang, M., Li, X., Wang, Y., Zhou, G., & Zhao, J. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00762 · Cited by 22
Bae, C., Hino, J., Hosoda, H., Miyazato, M., & Kangawa, K. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.08.031 · Cited by 29
Matuszyk, E., Sierka, E., Rodewald, M., Bae, H., Meyer, T., Kuś, E., Chłopicki, S., Schmitt, M. P., Popp, J., & Barańśka, M. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165763 · Cited by 19
van Son, K. C., Verschuren, L., Hanemaaijer, R., Reeves, H. L., Takkenberg, R. B., Drenth, J. P. H., Tushuizen, M. E., & Holleboom, A. G. (2023) · Cancers · doi:10.3390/cancers15041308 · Cited by 19
The pivotal role of dysregulated autophagy in the progression of non-alcoholic fatty liver disease
Shen, Q., Yang, M., Wang, S., Chen, X., Chen, S., Zhang, R., Xiong, Z., & Leng, Y. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1374644 · Cited by 15
Transcriptomic Analysis of Hepatic Cells in Multicellular Organotypic Liver Models
Tegge, A. N., Rodrigues, R. R., Larkin, A. L., Vu, L. T., Murali, T. M., & Rajagopalan, P. (2018) · Scientific Reports · doi:10.1038/s41598-018-29455-x · Cited by 15
Mo, H., Yue, P., Li, Q., Tan, Y., Yan, X., Liu, X., Xu, Y., Luo, Y., Palihati, S., Yi, C., et al. (2025) · Angiogenesis · doi:10.1007/s10456-025-09969-5 · Cited by 20
“Supporting this, in vitro experiments with LSEC cell lines demonstrated that fatty acids suppress the expression of pro-inflammatory chemokines, including CCL2, CXCL10, and CXCL16, thereby inhibiting the migration of monocytes [97].”
Geng, Y., Arroyave-Ospina, J. C., Buist‐Homan, M., Plantinga, J. A., Olinga, P., Reijngoud, D., van Vilsteren, F. G. I., Blokzijl, H., Kamps, J. A. A. M., & Moshage, H. J. (2023) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2022.109255 · Cited by 16
Liver Sinusoidal Endothelial Cells at the Crossroad of Iron Overload and Liver Fibrosis
Petrillo, S., Manco, M., Altruda, F., Fagoonee, S., & Tolosano, E. (2021) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8168 · Cited by 14
Kuś, E., Jasiński, K., Skórka, T., Czyżyńska-Cichoń, I., & Chłopicki, S. (2017) · Pharmacological Reports · doi:10.1016/j.pharep.2017.11.019 · Cited by 12
McMahan, R. H., Porsche, C. E., Edwards, M. G., & Rosen, H. R. (2016) · PLoS ONE · doi:10.1371/journal.pone.0168301 · Cited by 10
Self-citationMahmoud, S. Y., Svensson, F., Zoufir, A., Módos, D., Afzal, A. M., & Bender, A. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.8b00382 · Cited by 6
Immune and metabolic cross-links in the pathogenesis of comorbid non-alcoholic fatty liver disease
Kotlyarov, S. N. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i4.597 · Cited by 6
Luo, Z., Huang, C., Chen, J., Chen, Y., Yang, H., Wu, Q., Lu, F., & Zhang, T. E. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1323859 · Cited by 6
Wu, Y., Le, W., Zhang, H., & Zhu, Y. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123879 · Cited by 5
Li, X., Jin, K., Fang, J., Ma, X., He, J., Lu, A., Jia, Z., & Shi, A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1835197 · Cited by 4
“The progression from simple steatosis to steatohepatitis involves white blood cells adhering to the walls of sinusoidal blood vessels, then storming into the liver tissue to trigger the in fl ammatory response (62, 63).”
Dheedene, W., Verhulst, S., Demuynck, L., Callewaert, B., de Haan, W., Vinckier, S., Wauwe, J. V., Vandervoort, P., Lox, M., Stroobants, M., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-05881-6 · Cited by 3
“However, it remains unknown how (much) these agonists affect LSEC behavior, since it was recently shown that PPAR(α) signaling is active in LSECs at baseline already and also upon lipid challenge 1,23,31,32 .”
Chen, X., Jiang, Z., Gu, M., Feng, B., Xie, Z.-Q., Huang, M., Chen, Z., & Tang, M. (2022) · Research Square · doi:10.21203/rs.3.rs-1761623/v1 · Cited by 5
Sinusoidal cell interactions—From soluble factors to exosomes
Ortega‐Ribera, M., Babuta, M., & Szabó, G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95262-0.00002-4 · Cited by 1
Yin, M., Zhang, Y., Liu, S., & Li, X. (2026) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-026-00921-z · Cited by 2
“It is produced predominantly by hepatocytes [102], with additional contributions from LSECs [103], macrophages, and HSCs [104].”
Research progress of sinusoidal endothelial cells in nonalcoholic fatty liver disease
Cao, J., Yan, J., Wu, J., & Chen, Z. (2021) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v29.i21.1254
The Role of Liver Sinusoidal Endothelial Cells in NAFLD Disease
黄, 玥. (2024) · Pharmacy Information · doi:10.12677/pi.2024.133025
Pan, Y., Song, F., Liu, X., Zhang, Y., Zhang, J., Chen, S., Song, G., & Ren, L. (2025) · Research Square · doi:10.21203/rs.3.rs-7562588/v1
Pan, Y., Song, F., Liu, X., (8098), Y. Z., Zhang, J., Song, G., & Ren, L. (2026) · BMC Gastroenterology · doi:10.1186/s12876-026-04986-0 · Cited by 1
“By directing leukocyte trafficking and positioning, chemokine networks can contribute to hepatic immune-cell recruitment and activation in MASLD and shape downstream inflammatory mediator production and tissue immune organization [45].”
Ueda, Y., Kawaguchi, N., Inomata, Y., Arima, J., Ishida, M., Ito, Y., Lee, S., & Taniguchi, K. (2026) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70782 · Cited by 1
Metadata
- Authors
- McMahan, R. H., Porsche, C. E., Edwards, M. G., & Rosen, H. R.
- Affiliations
- University of Colorado Denver (US)
- Denver VA Medical Center (US)
- Corresponding author
- Rosen, Hugo R.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-07-25
- Volume
- 11
- Issue
- 7
- Pages
- e0159217
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4959750
- OpenAlex
- W2477382777
- Cited by
- 55
- References
- 42
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 5 · 2023: 6 · 2022: 8 · 2021: 4 · 2020: 6 · 2019: 5 · 2018: 6 · 2017: 3 · 2016: 1
- FWCI
- 4.69
- Type
- journal article
- Language
- en
- Update notices
- correction (2016-12-08)
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (K01 DKO96025)
- VA Merit Review Grant
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- non-alcoholic fatty liver disease, liver sinusoidal endothelial cells, free fatty acids, chemokines, steatosis, MCP-1, CXCL10, CXCL16, monocyte migration, inflammation, anti-inflammatory phenotype, gene expression profiling, lipid metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.